SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Gliatech (GLIA)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: chirodoc who wrote (678)3/14/1999 6:51:00 PM
From: NeuroInvestment   of 2001
 
Reading the prospects of neuropharm strategies which have yet to reach humans (the GLIA AD program) or show efficacy in humans (the H3 program) is mindbogglingly difficult--though one can find glimmers in the research, such as the nuggets that Richard Harmon manages to gather and disseminate. I am currently re-reviewing GLIA, but the short story is; while H3 is better understood and documented now than are the AD molecules hidden in Janssen's labs, even for H3 a best-case scenario would have approval in....2002 perhaps. However, since I devote much of my time to neuro tea leaf reading, I am constantly appraising companies who only have these early stage programs of promise, with no guarantees. GLIA truly is a company of two pipelines, but it is the known quantity of the ADCON program(s) that makes the neuro pipeline much less of a gamble than it is for companies who have nothing else with which to survive.
NeuroInvestment (www.neuroinvestment.com)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News